LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.64 -1.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6099999999999999

Max

1.71

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Aktsiakasum	-0.43
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	14M -28M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+78.57% upside

Turustatistika
By TradingEconomics
Turukapital	-3M 100M
Eelmine avamishind	3.44
Eelmine sulgemishind	1.64

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. nov 2025, 18:59 UTC

Suurimad hinnamuutused turgudel

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. nov 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. nov 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. nov 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. nov 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. nov 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Rev $2.6B >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q EPS $4.02 >TCOM

17. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Adj EPS 26c >JHX

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. nov 2025, 21:39 UTC

Tulu

James Hardie Industries 2Q Sales $1.29B >JHX

17. nov 2025, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 21:38 UTC

Tulu

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q EPS BRL2.47 >XP

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q Rev BRL4.67B >XP

17. nov 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. nov 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. nov 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. nov 2025, 19:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 18:20 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. nov 2025, 16:45 UTC

Omandamised, ülevõtmised, äriostud

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. nov 2025, 16:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 16:15 UTC

Tulu

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. nov 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. nov 2025, 15:22 UTC

Omandamised, ülevõtmised, äriostud

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. nov 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

78.57% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 78.57%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.